Nimodipine

CHEMBL1428 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
418.4 g/mol
LogP
3.1
Phase
4

A calcium channel blocker that is particularly active in brain blood vessels, helping to prevent dangerous narrowing of arteries after a brain bleed.

Berat Molekul

418,4000 g/mol

LogP

3,10

TPSA

120,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1

InChI

InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

Molecular Formula

C21H26N2O7

HBD / HBA

1 / 8

Ikatan yang Dapat Dirotasi

9

Atom Berat

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A calcium channel blocker that is particularly active in brain blood vessels, helping to prevent dangerous narrowing of arteries after a brain bleed.

Yes, Nimodipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1428. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4497. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.